News
FDA Office Favors Antibody-drug Conjugate for Advanced Multiple Myeloma
An office of the U.S. Food and Drug Administration (FDA has recommended that belantamab mafodotin, GlaxoSmithKline’s investigational...
Upcoming Patient Seminar: Whangarei Myeloma Seminar
Come along to our Whangarei Myeloma Patient Seminar, hosted by Myeloma New Zealand and Leukaemia & Blood cancer New Zealand. During the evening,...
Case Report Describes Late-onset MG in Man Treated for Multiple Myeloma
This post was originally published by Myasthenia Gravis News A 60-year-old man being treated for multiple myeloma was found to...
HealthTree® Launches HealthTree University for Multiple Myeloma Patients
This was originally posted by Cision PR Newswire SALT LAKE CITY, July 9, 2020 /PRNewswire/ -- HealthTree®, the first online portal...
FDA Places MELANI-01 Study for Multiple Myeloma on Hold After Safety Report Submission
This article was originally published by Cancer Network Cellectis recently announced the FDA placed its MELANI-01 trial treating multiple myeloma on...
Dr. Kumar on Stem Cell Mobilization in Multiple Myeloma
This article originally published by OncLive Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses stem cell mobilization multiple...
Ninlaro Maintenance Therapy Improves Survival in Patients Not Given ASCT, Trial Shows
First-line maintenance therapy with Ninlaro (ixazomib) significantly delays disease progression or death in adults with multiple...
Multiple myeloma triple therapy now on PBS
This article was originally published by Hostpital and Healthcare. Australians with newly diagnosed multiple myeloma (MM) can now access a treatment...
GNS Healthcare Launches In Silico Multiple Myeloma “Patient”
GNS Healthcare, a precision medicine company leveraging artificial intelligence to model individual patients’ response to drug treatment, have...
MRP a valuable risk assessment tool for newly diagnosed multiple myeloma
A clinical prediction model for myeloma has been shown to be “a robust and valuable tool” in a real-world population of Danish patients.
Dr. Hari on the Role of MRD in Multiple Myeloma
Parameswaran Hari, MD, MRCP, the Armand J. Quick/William F. Stapp Professor of Hematology, and the chief of the Division of Hematology/Oncology, Department of Medicine, at the Medical College of Wisconsin…
Study Identifies Independent Predictors of Smoldering Multiple Myeloma Progression
A series of molecular abnormalities in smoldering multiple myeloma that are independent predictors of progression to multiple myeloma were...